Key statistics
On Monday, Allogene Therapeutics Inc (ALLO:NSQ) closed at 2.58, 28.36% above the 52 week low of 2.01 set on Jul 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.72 |
---|---|
High | 2.74 |
Low | 2.58 |
Bid | 2.60 |
Offer | 2.75 |
Previous close | 2.70 |
Average volume | 1.82m |
---|---|
Shares outstanding | 209.11m |
Free float | 151.12m |
P/E (TTM) | -- |
Market cap | 564.60m USD |
EPS (TTM) | -1.59 USD |
Data delayed at least 15 minutes, as of Oct 07 2024 21:00 BST.
More ▼
Announcements
- Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference
- Allogene Therapeutics to Present Pre-Clinical Data Highlighting the Potential of ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Diseases, at the American College of Rheumatology (ACR) Convergence
- Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
- Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update
- Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update
- Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)
- Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse
- Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit
- Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
- Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update
More ▼